Markets | | Discounters Win In The Rush To Pantry-Load
It’s no secret the pandemic spurred a round of pantry-hoarding the likes of which we’ve never before seen. Staples giant and dividend powerhouse Clorox (CLX) said demand increases for some of its products topped 500% and that is no joke. 500%. ... Read the Full Story |
|
From Our Partners | | Matt Monaco started with a $2,000 trading account and no clear strategy. After two years of trial and error, he crossed $1 million in 2020.
Today his account sits at $3 million, generating roughly $100,000 a month using a repeatable system he calls The Income Blueprint.
He's revealing the exact five-step scan and three trading lanes behind it in a free live training. | | Reserve your seat and claim The Income Blueprint free |
|
Markets | |
With restaurant dining rooms only just starting to come back in a lot of places—some have been open for most of a month in at least some capacity—one thing was clear: when the going gets tough, America gets take-out. And take-out pizza was a very big deal in the last month, as reported... Read the Full Story |
|
Markets | | Shares of the enigmatic athleisure brand Under Armour (NYSE: UAA) (NYSE: UA) have been in a downtrend since peaking in July 2019 at $27.72 on the heels of its last upbeat earnings report. Management ate crow in the following quarters as they missed guidance and continued to lose credibility with shr... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Markets | | It’s Not Consensus That Matters
Autozone (AZO) made headlines this morning after it reported consensus-beating results for the calendar 1st quarter. While a consensus beat is a great thing, it does not make a stock a buy, especially if the outlook for future growth is in peril. In the case of... Read the Full Story |
|
Markets | | Fantasy sports betting platform Draft Kings (NASDAQ: DKNG) shares have accelerated as a pandemic beneficiary play. The absence of live sports events has caused fans to embark upon fantasy sports to meet their fix with the potential to win cash and prizes. Stay-in-shelter isolation mandates generated... Read the Full Story |
|
From Our Partners | | SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors.
Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | | Read Tilson's free analysis and find out what to do with your money |
|
Markets | |
Technology moves at a mile a minute these days. This is particularly true in the business world, which is rapidly evolving as a result of new and innovative companies that help companies handle their operations in better and more efficient ways. Look no further than some of the fintech companies t... Read the Full Story |
|
Markets | | Target Reports Results And Blows Past The Consensus
Target (TGT) reported earnings this morning and led me to a singular conclusion; tech is going to boom this year. I’m sure by now you’re thinking that I’m either crazy, Target is doing something behind the scenes you don’t ... Read the Full Story |
|
Markets | |
Have you been aching for a lunch of soup, salad and breadsticks at your local Olive Garden? If that's the case, then you're in luck; Darden Restaurants (NYSE: DRI) has a plan to open up almost two out of every three of its dining rooms by the end of the month, and it's not just Olive Garden, eithe... Read the Full Story |
|
Markets | | There’s A Lot Of Good News Out There
The stock market is often an irrational beast and never more so, seemingly than when it is discounting a future event. Take, for instance, the recent correction. The correction was sharp and swift, not because the economy was in decline but because of an e... Read the Full Story |
|
Markets | | Fertility benefits management company Progyny, Inc. (NASDAQ: PGNY) fills a void in health insurance coverage that the world’s leading companies embrace to attract and keep top talent. Infertility coverage that is not deemed ‘medically necessary’ is not covered by most health plans... Read the Full Story |
|
The Early Bird Stock Of The Day Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts. | | View Today's Stock Pick |
|
